Appendix S1. Supplementary Materials and Methods.

Figure S1. Control experiments for recording of NMDA mEPSCs under zero- Mg2+ condition. In zero-Mg2+ extracellular solution, the Mg2+ blockade of NMDA receptor channels was gradually relieved. Therefore, it is possible that the potentiation of mEPSCs was induced not by D1 activation but by the gradual release of Mg2+ block for NMDA receptor channels when cortical slices were incubated in zero-Mg2+ solution. To exclude this possibility, we analyzed the changes of mEPSCs for 15 min without application of SKF-81297. Under this condition, both frequency and amplitude of mEPSCs appeared to be stable, without significance (n = 4; p > 0.05 for both frequency and amplitude), suggesting the reliability of the recording and SKF-81297 effects.

Figure S2. Non-specificity because of secondary antibodies is negligible in immunostaining processes. (a–c) Mouse anti-NR2B antibody was included whereas anti-PSD95 was omitted in the primary antibody incubation; FITC conjugated goat-antimouse and Cy3-conjugated goat-anti-rabbit antibodies were included in the subsequent incubations. Specific staining of NR2B (a) and negligible non-specific staining from Cy3-conjugated goat-antirabbit antibody (b) were distinguished. In panels (d–f) however, only rabbit anti-PSD95 was included in the primary incubation whereas NR2B was omitted. Under this condition, the non-specific staining derived from FITC-conjugated goat anti-mouse antibody was minimal whereas the staining of PSD95 was strong. Scale bar = 10 μm.

Figure S3. The AMPA receptor-mediated currents were not affected by D1 agonist. Sample traces (a) and summary histograph (b) showing that neither frequency nor amplitude of mEPSCs recorded under −60 mV was changed by co-application SKF-81297 (1 μM) with APV (50 μM), TTX (1 μM), and picrotoxin (50 μM), indicating an unaltered pre-synaptic glutamate release (n = 6, p > 0.05).

Figure S4. D1 activation increases NMDA receptor NR1 clusters but not PSD95 in total staining. (a–i) Neurons treated with dimethyl sulfoxide (DMSO, 0.1%) as vehicle control (a, d, and g), D1 agonist SKF-81297 (b, e, and h), or SKF-81297 + D1 antagonist SCH-23390 (c, f, and i) were immunostained with NR1 and PSD95 antibodies. Scale bar = 10 μm. (j) Quantitative analysis of D1 effect on NR1 clusters and fluorescence intensity. Neurons treated with SKF81297 had significantly higher number of NR1 puncta and significantly greater fluorescence intensity (**< 0.01 for both cluster and fluorescence intensity). Neurons treated with SKF81297 + SCH23390, however, exhibited no significant change in either puncta number or fluorescent intensity compared with the vehicle-treated controls (> 0.05). (k) Quantitative analysis shows that D1 activation did not change PSD95 total staining, neither on PSD95 clusters nor fluorescence intensity (> 0.05).

As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer-reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.

JNC_6720_sm_FigS1-4.pdf272KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.